|
English
|
正體中文
|
简体中文
|
2809385
|
|
???header.visitor??? :
26970526
???header.onlineuser??? :
458
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"montesinos p"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-02-05T06:29:13Z |
Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
|
Perl A.E.;Martinelli G.;Cortes J.E.;Neubauer A.;Berman E.;Paolini S.;Montesinos P.;Baer M.R.;Larson R.A.;Ustun C.;Fabbiano F.;Erba H.P.;Di Stasi A.;Stuart R.;Olin R.;Kasner M.;Ciceri F.;Wen-Chien Chou;Podoltsev N.;Recher C.;Yokoyama H.;Hosono N.;Yoon S.-S.;Lee J.-H.;Pardee T.;Fathi A.T.;Liu C.;Hasabou N.;Liu X.;Bahceci E.;Levis M.J.; Perl A.E.; Martinelli G.; Cortes J.E.; Neubauer A.; Berman E.; Paolini S.; Montesinos P.; Baer M.R.; Larson R.A.; Ustun C.; Fabbiano F.; Erba H.P.; Di Stasi A.; Stuart R.; Olin R.; Kasner M.; Ciceri F.; WEN-CHIEN CHOU; Podoltsev N.; Recher C.; Yokoyama H.; Hosono N.; Yoon S.-S.; Lee J.-H.; Pardee T.; Fathi A.T.; Liu C.; Hasabou N.; Liu X.; Bahceci E.; Levis M.J. |
| 臺大學術典藏 |
2021-02-05T06:29:13Z |
Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
|
Perl A.E.;Martinelli G.;Cortes J.E.;Neubauer A.;Berman E.;Paolini S.;Montesinos P.;Baer M.R.;Larson R.A.;Ustun C.;Fabbiano F.;Erba H.P.;Di Stasi A.;Stuart R.;Olin R.;Kasner M.;Ciceri F.;Wen-Chien Chou;Podoltsev N.;Recher C.;Yokoyama H.;Hosono N.;Yoon S.-S.;Lee J.-H.;Pardee T.;Fathi A.T.;Liu C.;Hasabou N.;Liu X.;Bahceci E.;Levis M.J.; Perl A.E.; Martinelli G.; Cortes J.E.; Neubauer A.; Berman E.; Paolini S.; Montesinos P.; Baer M.R.; Larson R.A.; Ustun C.; Fabbiano F.; Erba H.P.; Di Stasi A.; Stuart R.; Olin R.; Kasner M.; Ciceri F.; WEN-CHIEN CHOU; Podoltsev N.; Recher C.; Yokoyama H.; Hosono N.; Yoon S.-S.; Lee J.-H.; Pardee T.; Fathi A.T.; Liu C.; Hasabou N.; Liu X.; Bahceci E.; Levis M.J. |
| 臺大學術典藏 |
2021-02-05T06:29:12Z |
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
|
Smith C.C.;Levis M.J.;Perl A.E.;Martinelli G.;Neubauer A.;Berman E.;Montesinos P.;Baer M.R.;Larson R.A.;Wen-Chien Chou;Yokoyama H.;Recher C.;Yoon S.-S.;Hill J.E.;Rosales M.;Bahceci E.; Smith C.C.; Levis M.J.; Perl A.E.; Martinelli G.; Neubauer A.; Berman E.; Montesinos P.; Baer M.R.; Larson R.A.; WEN-CHIEN CHOU; Yokoyama H.; Recher C.; Yoon S.-S.; Hill J.E.; Rosales M.; Bahceci E. |
| 臺大學術典藏 |
2021-02-05T06:29:12Z |
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
|
Smith C.C.;Levis M.J.;Perl A.E.;Martinelli G.;Neubauer A.;Berman E.;Montesinos P.;Baer M.R.;Larson R.A.;Wen-Chien Chou;Yokoyama H.;Recher C.;Yoon S.-S.;Hill J.E.;Rosales M.;Bahceci E.; Smith C.C.; Levis M.J.; Perl A.E.; Martinelli G.; Neubauer A.; Berman E.; Montesinos P.; Baer M.R.; Larson R.A.; WEN-CHIEN CHOU; Yokoyama H.; Recher C.; Yoon S.-S.; Hill J.E.; Rosales M.; Bahceci E. |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
